By analyzing the potential predictive value of age according to hormone receptor status, similar results were observed; there was only an apparent trend for a smaller benefit of pertuzumab in patients with hormone receptor–negative disease, particularly in the young cohort ( Supplementary Figures 1 and 2 and Table 5 , available online).
← all excerpts
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.
1
—
—